Entera Bio Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Entera Bio Ltd in the second quarter 2026?
Entera Bio Ltd achieved a return on average equity (ROE) of 20.82 % in its second quarter 2026, which is below Entera Bio Ltd 's average return on equity, which stands at 41.81%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Biotechnology & Pharmaceuticals industry 11 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 98 to 111.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-57.89 %	-44.85 %	62.14 %	136.11 %	-
Y / Y Net Income Change	-	36.54 %	-	5.93 %	-
Net Income (TTM) in Millions	2	12	11	6	6
Return On Equity (TTM)	20.82 %	87.97 %	70.43 %	40.47 %	46.01 %
ENTX's Total Ranking	# 111	# 98	# 93	# 95	# 71
Equity (TTM) in Millions	7	11	13	15	17
Seq. Equity Change	-32.01 %	-18.43 %	-14 %	-11.72 %	-10.96 %
Seq. Net Income Change	-	16.21 %	-5.75 %	20.48 %	3.47 %

Back to ENTX Management Effectiveness >> ENTX's 5 Years Annual ROE >> Compare ENTX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 12
Sector	# 80
Overall	# 111

Return On Equity Statistics
High	Average	Low
103.4 %	41.81 %	-43.99 %
		(Dec 31 2022)

ENTX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	13	8	10	12	23
Y / Y Equity Change	62.14 %	-22.2 %	-11.64 %	-47.91 %	200.47 %
Net Income in Millions	11	10	9	13	12
Y / Y Net Income Change	19.89 %	7.33 %	-31.99 %	7.25 %	-
Return On Equity	87.31 %	118.08 %	85.59 %	111.2 %	54.01 %

Back to ENTX Management Effectiveness >> ENTX's 5 Years Annual ROE >> Compare ENTX ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 87.31 %, despite net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ENTX's' Return on Equity at Yahoo Finance
ENTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ENTX's Competitors
Subscribers only: Roe for Entera Bio Ltd 's Suppliers
Subscribers only: Return On Equity for ENTX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %

Date modified: 2026-08-14T19:56:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.